The Clarks Journey. Our journey. Our story. One day at a time. Hope, Family, Faith, Strength, Together. A brighter tomorrow.

A Note from Brad….

Oncologist Office Visit — Discussing the Diagnosis and Possible Treatment Plan Options

My oncologist confirmed that my diagnosis is Stage IVA lung cancer. He described the tumor as slow growing—comparing its appearance to an ink-pen dot in 2019 versus roughly the size of a pea in 2026.

There was encouraging news, too. My abdominal and pelvic CT scan and brain MRI showed no evidence of cancer in those areas. Based on the testing so far, the known disease appears confined to my chest. My labs also look good.

We’re still waiting for the specialized DNA/RNA testing through CARIS on tissue from my original 4R lymph node biopsy. That testing may help confirm—or add to—what the blood-based testing has already shown.

The blood test did not identify any actionable genetic driver mutations. Based on those results, targeted therapy is not currently an option, but the tissue testing could still provide additional information.

The possible paths ahead

If the CARIS laboratory cannot complete the panel because there isn’t enough tissue, we discussed three possible paths.

Path 1: Obtain another tissue biopsy

One option is another biopsy, possibly directly from the lung tumor, to obtain enough tissue for additional molecular testing.

My understanding is that a tumor may not release enough tumor DNA into the bloodstream for a blood test to detect an existing mutation. A negative blood result therefore may not tell the whole story. That is why confirming the findings through tissue testing matters to us.

Path 2: Chemotherapy combined with immunotherapy

Another option discussed was chemotherapy combined with one immunotherapy drug, if no actionable mutation is identified.

Path 3: Two immunotherapy drugs without chemotherapy

My oncologist also discussed a combination of two immunotherapy drugs without traditional chemotherapy. We talked about clinical-trial evidence and my PD-L1 result of 0% as part of reviewing whether this approach would be appropriate for me.

One concern we discussed was the potential for significant immune-related side effects and toxicity. My understanding is that combining two immunotherapy drugs can increase certain risks, although experiencing severe side effects is not a certainty. The possible benefits and risks are part of the decision we still need to make.

What I’ve decided for now

For now, we’re going to wait for the current CARIS panel to see whether the tissue from my original lymph node biopsy is sufficient. We expect that could take another week or two.

If there isn’t enough tissue, I’ve asked my oncologist to contact my pulmonologist about whether a biopsy directly through the chest wall into the upper-lung tumor would be possible, rather than another bronchoscopy.

If that approach is feasible, we would likely consider another biopsy for CARIS testing to look again for an actionable mutation.

If no actionable mutation is found and targeted therapy remains unavailable, the decision would come down to chemotherapy with immunotherapy or double immunotherapy.

One question I still need clarified

My oncologist mentioned that we could start one treatment approach and potentially pivot to another if needed. I need to clarify exactly what he meant.

Was he referring to changing treatment if later testing identifies an actionable mutation? Or was he discussing changing between double immunotherapy and chemotherapy with immunotherapy if side effects become too difficult?

That is something I want to understand clearly before making the final decision.

For now, that’s where we stand—waiting for the tissue-testing results and working through the possible next steps.

Most Common Side Effects experienced:

Common, Manageable Side Effects

Many patients experience mild-to-moderate side effects that usually arise within the first few weeks or months of treatment:

  • Fatigue and weakness: The most frequently reported symptom, affecting over half of all patients.
  • Skin reactions: Rashes, dry skin, and intense itching (pruritus).
  • Digestive issues: Mild diarrhea, nausea, vomiting, or a decreased appetite.
  • Musculoskeletal pain: General aches or localized pain in the muscles, joints, or bones.
  • Respiratory symptoms: A mild cough or shortness of breath

← Back to all updates

Your message is welcome. Replies are reviewed before appearing on the site.

Add an emoji to your message:
Comment Email Notifications
Notify of
guest

0 Comments

“Grateful for today. Hopeful for tomorrow.”